{
  "citations" : [
    {
      "id" : 7283333,
      "title" : "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "_sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
      "authors" : [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "crossReferences" : [
        {
          "id" : 769250885,
          "resource" : "PubMed",
          "resourceId" : "21412232",
          "_url" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
          "version" : 0
        },
        {
          "id" : 1449247827,
          "resource" : "DOI",
          "resourceId" : "10.1038/clpt.2011.34",
          "_url" : "http://dx.doi.org/10.1038%2Fclpt.2011.34",
          "version" : 0
        }
      ],
      "day" : -1,
      "hasKeyword" : true,
      "journal" : "Clinical pharmacology and therapeutics",
      "meshTerms" : [
        "Animals",
        "Aryl Hydrocarbon Hydroxylases",
        "Cytochrome P-450 CYP2C9",
        "Drug Administration Schedule",
        "Drug-Related Side Effects and Adverse Reactions",
        "Humans",
        "Pharmaceutical Preparations",
        "Pharmacogenetics",
        "Practice Guidelines as Topic"
      ],
      "month" : 5,
      "nonHuman" : false,
      "objCls" : "Literature",
      "page" : "662-73",
      "pediatric" : false,
      "pgkbPublication" : false,
      "pubDate" : "2011-05-01T00:00:00-07:00",
      "pubmedMeshTerms" : [],
      "summary" : "Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).",
      "terms" : [],
      "type" : "Literature",
      "version" : 4,
      "volume" : "89",
      "year" : 2011
    }
  ],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166104991",
    "name" : "Annotation of DPWG Guideline for abacavir and HLA-B",
    "alternateDrugAvailable" : true,
    "cancerGenome" : false,
    "crossReferences" : [],
    "dosingInformation" : false,
    "hasTestingInfo" : true,
    "history" : [
      {
        "id" : 1183704435,
        "date" : "2011-08-10T00:00:00-07:00",
        "type" : "Create",
        "version" : 0
      },
      {
        "id" : 1450414978,
        "date" : "2019-05-23T11:11:09.217-07:00",
        "description" : "Annotation current with November 2018 DPWG Guideline release",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450815696,
        "date" : "2019-09-25T14:04:52.813-07:00",
        "description" : "Changes based on August 2019 guidelines",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450956260,
        "date" : "2020-01-31T13:13:12.226-08:00",
        "description" : "Updated link to 2011 DPWG methods",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450962482,
        "date" : "2020-02-10T08:05:42.502-08:00",
        "description" : "Fixed links to 2018 and 2019 guideline pdfs.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451704234,
        "date" : "2022-03-03T16:33:32.514-08:00",
        "description" : "Annotation current with May 2021 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451705880,
        "date" : "2022-03-07T08:46:32.156-08:00",
        "description" : "Added information about preemptive genotyping",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451732874,
        "date" : "2022-03-28T09:57:46.431-07:00",
        "description" : "Annotation current with February 2022 DPWG guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451733240,
        "date" : "2022-03-28T14:20:56.013-07:00",
        "description" : "Updated link to testing guidance page",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451741440,
        "date" : "2022-04-05T11:07:38.988-07:00",
        "description" : "Added testing guidance tag",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451883860,
        "date" : "2022-09-16T08:51:13.544-07:00",
        "description" : "Fixed link to gene information document and added explanatory note",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452146441,
        "date" : "2023-07-03T13:39:45.539-07:00",
        "description" : "Annotation current with May 2023 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1452411042,
        "date" : "2024-03-18T08:50:47.096-07:00",
        "description" : "Updated links for risk analysis pdf and preemptive testing page.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452422720,
        "date" : "2024-03-27T10:56:30.830-07:00",
        "description" : "Added Alternate Drug tag",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":7283333,"title":"Pharmacogenetics: from bench to byte--an update of guidelines.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21412232","crossReferences":[{"id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"},{"id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"}],"objCls":"Literature","pubDate":"2011-05-01T00:00:00-07:00","terms":[],"type":"Literature"},
      {"id":15103288,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","crossReferences":[{"id":1450815695,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"},
      {"id":15102465,"title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","crossReferences":[{"id":1450415575,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : false,
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [
      {
        "objCls" : "Haplotype",
        "id" : "PA165987830",
        "symbol" : "HLA-B*57:01",
        "name" : "*57:01",
        "version" : 6
      }
    ],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA448004",
        "name" : "abacavir",
        "version" : 13
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA35056",
        "symbol" : "HLA-B",
        "name" : "major histocompatibility complex, class I, B",
        "version" : 40
      }
    ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1447982006,
      "html" : "<p>Avoid abacavir for patients who have the HLA-B*57:01 allele (patients who are &quot;HLA-B*57:01-positive&quot;).</p>\n",
      "version" : 1
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1447982005,
      "html" : "<h3 id=\"august-2019-update\">August 2019 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 and recommends avoiding abacavir.</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_August_2019.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/DPWG_August_2019.pdf\">Dutch guidelines August 2019 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>HLA-B*5701</td>\n<td>abacavir</td>\n<td>HLA-B*5701-positive patients have a strongly increased risk of a hypersensitivity reaction to abacavir. 48% of the HLA-B*5701-positive patients develop a severe and potentially life-threatening hypersensitivity reaction to abacavir</td>\n<td>Abacavir is contra-indicated for HLA-B*5701-positive patients.<br/>1. Avoid abacavir.</td>\n</tr>\n</tbody>\n</table>\n<p><a download=\"DPWG_HLA_abacavir_2356.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/DPWG_HLA_abacavir_2356.pdf\">Read for more information about this recommendation</a>, <a download=\"HLAs.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/HLAs.pdf\">Read about gene information from DPWG</a></p>\n<h4 id=\"preemptive-genotyping\">Preemptive genotyping</h4>\n<p>Excerpts from the <a download=\"DPWG_HLA_abacavir_2356.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/DPWG_HLA_abacavir_2356.pdf\">DPWG risk analysis document</a> for abacavir and HLA-B:</p>\n<blockquote class=\"blockquote\">\n<p>The KNMP Pharmacogenetics Working Group considers genotyping before starting abacavir to be essential for drug safety. Genotyping must be performed before drug therapy has been initiated to guide drug selection.</p>\n</blockquote>\n<p><a href=\"/page/dpwgPreemptiveGenotyping\">Read more about how DPWG assigns their recommendations for preemptive genotyping.</a></p>\n<h3 id=\"november-2018-update\">November 2018 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 and give the same recommendation as in 2011.</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_November_2018.pdf\" href=\"https://api.clinpgx.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>HLA-B*5701</td>\n<td>abacavir</td>\n<td>HLA-B*5701-positive patients have a strongly increased risk of a hypersensitivity reaction to abacavir.</td>\n<td>Abacavir is contra-indicated for HLA-B*5701-positive patients.<br/>1. Advise the prescriber to prescribe an alternative according to the current guidelines.</td>\n</tr>\n</tbody>\n</table>\n<h3 id=\"2011-guideline\">2011 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 [Article:<a href=\"/pmid/21412232\">21412232</a>]. They conclude that an alternate drug should be selected for patients who are HLA-B*57:01 positive.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Genotype</th>\n<th>Therapeutic Dose Recommendation</th>\n<th>Level of Evidence</th>\n<th>Clinical Relevance</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>HLA-B*57:01</td>\n<td>Select alternative drug</td>\n<td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td>\n<td>Clinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia &lt; 0.5x109/l; leucopenia &lt; 1.0x109/l; thrombocytopenia &lt; 25x109/l; life-threatening complications from diarrhea.</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>*See <a href=\"/page/dpwg\">Methods</a> or [Article:<a href=\"/pmid/18253145\">18253145</a>] for definition of &quot;good quality.&quot;</li>\n<li>S: statistically significant difference.</li>\n</ul>\n",
      "version" : 19
    },
    "version" : 41
  }
}